Progenity (PROG) Appoints Adi Mohanty as CEO

Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the appointment of Adi Mohanty as Chief Executive Officer of the company, effective November 8, 2021. Mr. Mohanty also joins the Progenity Board of Directors.

“As we complete the execution of our strategic transformation, we are continuing to build biotechnology and biotherapeutics leadership capabilities to help ensure our success,” said Eric d’Esparbes, Chief Financial Officer and interim CEO. “To this end, we are delighted to welcome Adi Mohanty to Progenity as Chief Executive Officer. We believe he is the right person to lead Progenity into this next phase of growth as we advance the discovery, development, and delivery of therapeutics.”

“Progenity’s innovative platforms show substantial promise to change the way we diagnose and treat many complex diseases,” said Mr. Mohanty. “I am excited to be taking on this role, and I look forward to working alongside the Progenity board, management, and employees to accelerate the company’s transformation and realize the potential of its innovative technologies.”

Adi Mohanty is an experienced biotech business leader with a track record of several successful product development and approvals followed by rapid commercialization. Previously, he served as CEO of BioTime, where during his tenure, the company advanced its platform science to develop product candidates from the lab into mid- and late-stage clinical trials and unlocked value through strategic transactions, resulting in a better-capitalized company, poised to build substantial value for shareholders through renewed focus on clinical progress.

Adi formerly served as vice president at Transkaryotic Therapies, which was acquired by Shire PLC. Throughout a decade at Shire, he held several executive positions spanning global technical operations, product development, and commercial operations, culminating in the role of President, Regenerative Medicine. Earlier in his career, he held a variety of management positions in the bioscience division of Baxter Healthcare. Additionally, he has served as a board member for OncoCyte, a diagnostics company that he helped take public. Mr. Mohanty received his MBA at Saint Mary’s College, California. He also holds a Master of Science in Chemical Engineering from Clarkson University.

You May Also Be Interested In

• CarMax executive to depart at year-end with consulting deal
• Plus Therapeutics rebrands to Cerenome, changes ticker to CNSY
• Arrive AI CFO and board member resign within days of each other